• Explore /
  • Poster
  • / PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.

PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.

Abstract Poster

Authors

Michael Morris

Michael J. Morris

Memorial Sloan Kettering Cancer Center and Weil Cornell Medical College, New York, NY

Michael J. Morris , Nicholas J. Vogelzang , A. Oliver Sartor , Alison A. Armour , Richard Adam Messmann , Michael Groaning , Adam Robarts , Anthony W. Tolcher , Michael S. Gordon , Hani M. Babiker , Phillip Kuo , Megan Kearney , Adam Jendrisak , Yipeng Wang , Mark Andrew Landers , Daniel Peter Petrylak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02202447

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 272)

DOI

10.1200/JCO.2018.36.6_suppl.272

Abstract #

272

Poster Bd #

N4

Abstract Disclosures

Similar Posters

First Author: Siyuan S Guo

First Author: Carissa Chu

First Author: Michael J. Morris

First Author: Michael J. Morris